Clindamycin clearance during Cytosorb ® hemoadsorption: A case report and pharmacokinetic study

Abstract

Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infections are rare but associated with very high mortality rates. We report the case of a 14-year-old patient with Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infection and Influenza B pneumonia requiring veno-arterial extra-corporeal membrane oxygenator for refractory shock. In the absence of response to conventional therapy, we have inserted a Cytosorb® cartridge within the extra-corporeal membrane oxygenator circuit. A spectacular decrease in vasopressor requirements followed. Since clindamycin, a key component of Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus treatment, might be removed by Cytosorb® hemoadsorption, we have performed serial plasma concentrations measurements of the drug. Based on these measurements, we were able to develop a pharmacokinetic model incorporating variable plasma clearance. Patient’s exposure was estimated before, during and after Cytosorb® hemoadsorption. According to this model, Cytosorb® hemoadsorption did not seem to result in significant clindamycin removal. Cytosorb® hemoadsorption during Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infection appears safe and feasible and no adaptation of clindamycin dosage seems necessary

Keywords

Adsorbents antibiotics hemoperfusion infection paediatric ECMO plasma clearance sepsis treatment of bacterial infections artificial kidney apheresis & detoxification techniques

Get full access to this article

View all access options for this article.

References

Poli

Rimmele

Schneider

AG.

Hemoadsorption with CytoSorb^®. Intensive Care Med. Epub ahead of print 16 November 2018. DOI: 10.1007/s00134-018-5464-6.

Malard

Lambert

Kellum

JA.

In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 2018; 6(1): 12.

Gruda

Ruggeberg

K-G

O’Sullivan

et al . Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS ONE 2018; 13: e0191676.

Turner

Sriskandan

Panton-Valentine leucocidin expression by Staphylococcus aureus exposed to common antibiotics. J Infect 2015; 71(3): 338–346.

Gillet

Issartel

Vanhems

et al . Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359(9308): 753–759.

Lina

Piemont

Godail-Gamot

et al . Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29(5): 1128–1132.

Stevens

Salmi

et al . Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195(2): 202–211.

Smith

Gonzalez

Goldman

et al . Pharmacokinetics of clindamycin in obese and nonobese children. Antimicrob Agents Chemother 2017; 61(4): e02014–e02016.

Lees

Rosenberg

Hurtado-Doce

et al . Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leukocidin-positive Staphylococcus aureus pneumonia and H1N1. J Artif Organs 2016; 19(4): 399–402.

10.

Loffler

Hussain

Grundmeier

et al . Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. Plos Pathog 2010; 6(1): e1000715.

11.

Diep

Chan

Tattevin

et al . Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 2010; 107(12): 5587–5592.

12.

Morris

Gray

Giovannelli

Early report: the use of Cytosorb™ haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc 2015; 16(3): 257–264.

13.

David

Thamm

Schmidt

BMW

et al . Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care 2017; 5: 12.

14.

Trotman

Williamson

Shoemaker

et al . Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41(8): 1159–1166.

15.

Kubin

Dzierba

The effects of continuous renal replacement on anti-infective therapy in the critically ill. J Pharm Pract 2005; 18: 109–117.